ClinicalTrials.gg
Sign In
CompletedNCT02786654Updated Jun 18, 2019

β Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure

An observational study in Acute Myocardial Infarction, sponsored by University of Leeds. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-06-18.

Sponsored by University of Leeds · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
179,810
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The aim of the study is to investigate the association between the use of β blockers and mortality among hospital survivors of acute myocardial infarction without heart failure.

02

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • Acute myocardial infarction
  • mortality
  • evidence-based care
  • Myocardial Ischaemia National Audit Project
  • β blockers
03

In context

Lead sponsor

University of Leeds is the lead sponsor of 206 studies on the registry; 25 are open to participants now.

Browse University of Leeds studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprised of 179,810 in hospital survivors of acute myocardial infarction without heart failure recorded in the Myocardial Ischaemia National Audit Project registry between 2007 and June 2013

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute myocardial infarction patients only
  • aged 18 to 100 years

Exclusion criteria

Exclusion Criteria:

  • other final diagnosis besides acute myocardial infarction
  • died in-hospital
  • patients with missing mortality data
  • aged > 100
  • patients with previous acute myocardial infarction or angina
  • patients who have received coronary interventions before
  • patients with heart failure
  • patients with β blocker prior use
  • patients contraindicated for β blocker use
  • patients with use of a loop diuretic
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
179,810 participants (actual)
Target follow-up
6 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. All cause mortality

    Time frame: 1 year

Secondary outcomes

  1. All cause mortality

    Time frame: 6 months

  2. All cause mortality

    Time frame: 30 days

07

Study locations

1 site
  • University of Leeds
    Leeds, LS2 9JT, United Kingdom
08

References and documents

Publications

  • Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, Danchin N, Deanfield JE, Hemingway H, Fox KAA, Timmis AD, Gale CP. beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017 Jun 6;69(22):2710-2720. doi: 10.1016/j.jacc.2017.03.578. PubMed 28571635 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2016
First posted
Jun 1, 2016
Start
Jan 2007
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Jun 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02786654
Lead sponsor
University of Leeds
Responsible party
Tatendashe Bernadette Dondo (Research assistant, University of Leeds) — Principal investigator
First posted
Jun 1, 2016
Start date
Jan 2007
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jun 18, 2019

Study contacts

Chris P Gale, FRCP
principal investigator · University of Leeds
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University of Leeds →

Start the discussion